Want to see HK:6669 full AI Analyst Report?
6669 Stock Chart & Stats
HK$14.16
-HK$0.14(-2.42%)
At close: 4:00 PM EST
HK$14.16
-HK$0.14(-2.42%)
Day’s Range― - ―
52-Week RangeHK$7.54 - HK$15.47
Previous CloseN/A
Volume343.13K
Average Volume (3M)462.19K
Market Cap
HK$2.37B
Enterprise ValueHK$2.03B
Total Cash (Recent Filing)HK$995.38M
Total Debt (Recent Filing)HK$236.13M
Price to Earnings (P/E)16.3
Beta1.14
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.34
Shares Outstanding313,389,160
10 Day Avg. Volume400,669
30 Day Avg. Volume462,190
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.51
Price to Sales (P/S)5.75
P/FCF Ratio25.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.45
Revenue Forecast (FY)HK$732.25M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueThe business model includes procedure-specific consumables that are replenished per case, creating repeat hospital purchasing and durable revenue streams. This drives lifetime customer value, supports predictable base demand, and helps commercial teams scale adoption across facilities over quarters.
High Gross And Improving Net MarginsGross margins near 72% and a step-up in net margin to ~18.5% reflect structural product profitability and operating leverage in manufacturing and pricing. Sustained high gross margins give room for SG&A and R&D reinvestment, supporting durable profitability if product mix and pricing hold.
Stronger Cash Generation In 2025Substantially stronger OCF and FCF in 2025 improved financial flexibility and funding for commercialization or product development without heavy new borrowing. High FCF conversion provides durable support for capex, working capital and strategic investment over multiple quarters.
Bears Say
Historical Earnings And Balance-sheet VolatilityPast periods of losses and a previously negative equity base show the firm's earnings and capitalization have been cyclical. Such historical volatility raises the risk that current profitability gains could reverse in adverse procedure-volume or pricing environments, requiring monitoring across cycles.
Uneven Cash Flow And Recent FCF DeclineDespite 2025 improvement, FCF fell year-over-year and cash flows were negative in recent prior years, indicating sensitivity to working capital and procedure volumes. This unevenness could constrain consistent reinvestment or create funding pressure if margins or sales soften.
Dependence On Hospital Adoption & Regulatory ApprovalsRevenue and growth hinge on winning hospital procurement, physician adoption, and regulatory registrations. These are structural bottlenecks with long sales cycles and possible reimbursement or approval delays, which can impede scaling and make revenue growth lumpy over multiple quarters.
Acotec Scientific Holdings Limited News
6669 FAQ
What was Acotec Scientific Holdings Limited’s price range in the past 12 months?
Acotec Scientific Holdings Limited lowest stock price was HK$7.54 and its highest was HK$15.47 in the past 12 months.
What is Acotec Scientific Holdings Limited’s market cap?
Acotec Scientific Holdings Limited’s market cap is HK$2.37B.
When is Acotec Scientific Holdings Limited’s upcoming earnings report date?
Acotec Scientific Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 59 days.
How were Acotec Scientific Holdings Limited’s earnings last quarter?
Acotec Scientific Holdings Limited released its earnings results on Mar 26, 2026. The company reported HK$0.112 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.112.
Is Acotec Scientific Holdings Limited overvalued?
According to Wall Street analysts Acotec Scientific Holdings Limited’s price is currently Overvalued.
Does Acotec Scientific Holdings Limited pay dividends?
Acotec Scientific Holdings Limited does not currently pay dividends.
What is Acotec Scientific Holdings Limited’s EPS estimate?
Acotec Scientific Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acotec Scientific Holdings Limited have?
Acotec Scientific Holdings Limited has 313,389,160 shares outstanding.
What happened to Acotec Scientific Holdings Limited’s price movement after its last earnings report?
Acotec Scientific Holdings Limited reported an EPS of HK$0.112 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.51%.
Which hedge fund is a major shareholder of Acotec Scientific Holdings Limited?
Currently, no hedge funds are holding shares in HK:6669
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort NeuroTech Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---